While the spotlight often shines on flashy startups and tech unicorns, a pharmaceutical brand you’ve probably never heard of just crossed a major milestone — and it’s doing
While the spotlight often shines on flashy startups and tech unicorns, a pharmaceutical brand you’ve probably never heard of just crossed a major milestone — and it’s doing it by going deep into tier-II and tier-III India.
Meet Aqualab, the retail division of Laborate Pharmaceuticals, which just hit ₹108 crore in revenue in FY 2023–24, up from ₹76 crore the previous year. Now, they’re setting sights on something bigger: ₹250 crore by FY 2025–26.
And they’re doing it fast — without the glitz, without the noise.
Founded in 2022, Aqualab has built a powerful Direct-to-Retail (DTR) engine that’s scaling rapidly across India’s pharmaceutical market. What makes them different?
This is a volume-driven, last-mile-focused growth strategy that’s clearly working. In just three years, Aqualab has cracked a model that many traditional pharma players are still trying to figure out.
According to Arpit Bhatia, Managing Director at Laborate Pharmaceuticals:
“Crossing ₹100 crore in three years demonstrates how quickly the Direct-to-Retail model is scaling in India. We are now targeting ₹250 crore by FY 25–26, with non-metro markets expected to contribute 42% of incremental growth.”
To hit that number, Aqualab plans to:
The bet? India’s under-served markets will drive the next big wave in pharma retail.
Aqualab’s growth isn’t happening in isolation. It aligns perfectly with some of India’s biggest economic and policy trends:
With more people trusting generics and pharma distribution becoming more organized, Aqualab is in the right place at exactly the right time.
A key part of Aqualab’s success lies in Laborate Pharmaceuticals’ state-of-the-art manufacturing infrastructure. The company’s plants are:
This isn’t just helping them grow fast — it’s helping them grow right.
The brand’s commitment to affordability and accessibility is backed by a strong focus on quality and compliance, allowing them to build trust in both urban and rural markets.
Aqualab isn’t stopping at domestic expansion. The next phase of growth will focus on:
As the market evolves, Aqualab wants to be more than just a retail pharma brand — it wants to be a next-gen pharma engine powering both India and beyond.
While everyone’s busy looking at startups disrupting things, Aqualab is quietly dominating India’s pharma retail game by focusing on scale, access, and smart execution.
With strong infrastructure, aggressive goals, and a strategy rooted in Bharat—not just India—₹250 crore doesn’t look like a moonshot. It looks inevitable.
